Michel Vounatsos

Michel Vounatsos. A French business executive, he is best known for serving as the chief executive officer of the biotechnology company Biogen from 2017 to 2022. His tenure was marked by the high-stakes launch and subsequent controversy surrounding the Alzheimer's drug aducanumab, as well as significant strategic shifts for the company. Vounatsos brought a global commercial perspective from a long career in the pharmaceutical industry, particularly with Merck & Co., before transitioning to biotech leadership.

Early life and education

Michel Vounatsos was born on December 21, 1961, in Marseille, France. He pursued his higher education in the field of medicine, graduating as a doctor of medicine from the University of Paris. His medical background provided a foundational understanding of clinical practice and patient care, which later informed his commercial and strategic decisions in the pharmaceutical industry. Following his medical studies, he further expanded his business acumen by completing an executive program at the prestigious INSEAD business school in Fontainebleau.

Career at Biogen

Vounatsos began his career in the pharmaceutical sector in 1990 at Merck & Co., where he held roles of increasing responsibility across Europe and the United States over nearly three decades. His positions included leadership in marketing and general management, culminating in his role as president of the company's Primary Care business unit. In 2016, he made a pivotal career move by joining Biogen as its executive vice president and chief commercial officer, tasked with overseeing global commercial operations. His rapid ascent continued, and he was appointed to the company's board of directors that same year, succeeding George A. Scangos as CEO in January 2017.

Leadership and strategic initiatives

As CEO, Vounatsos initiated a major strategic review to streamline Biogen's operations and focus its research pipeline. A key early move was the significant restructuring announced in 2017, which included layoffs and a shift away from research in areas like ophthalmology and acute neurology. His strategy centered on deepening investment in core neuroscience areas, including Alzheimer's disease, multiple sclerosis, and spinal muscular atrophy. The most defining initiative of his tenure was the pursuit of regulatory approval for aducanumab, developed in partnership with Eisai. Following a controversial advisory committee meeting with the U.S. Food and Drug Administration, the drug received accelerated approval in June 2021, becoming the first new therapy for Alzheimer's disease in nearly two decades. He also oversaw the launch of treatments like Vumerity for MS and navigated the patent challenges for the blockbuster drug Tecfidera.

Controversies and challenges

The approval and commercialization of aducanumab (marketed as Aduhelm) generated intense controversy and presented significant challenges. The drug's clinical trial data was met with skepticism from many in the scientific community, including experts on the FDA's advisory panel, and its high annual price sparked debates about healthcare costs, leading to a subsequent price cut. Furthermore, the decision by the Centers for Medicare & Medicaid Services to severely restrict coverage for the drug drastically limited its market potential. These events, combined with declining revenues from Biogen's established multiple sclerosis franchise, placed the company under considerable financial and reputational pressure during Vounatsos's final years as CEO.

Personal life and recognition

Michel Vounatsos is married and has two children. He maintains a relatively private personal life outside of his professional endeavors. During his career, he has been recognized for his leadership in the life sciences industry, participating in forums like the Forbes Healthcare Summit and engaging with the broader biotechnology community. Following his departure from Biogen in November 2022, as part of a broader leadership transition, he has taken on advisory roles. He continues to be based in the Boston area, a major hub for the biotechnology and pharmaceutical industries. Category:1961 births Category:Living people Category:French businesspeople Category:Biogen people Category:University of Paris alumni Category:INSEAD alumni Category:People from Marseille